1. Hamanaka, Natsuki, Nakanishi, Yoshito, Mizuno, Takakazu, Ishii, Nobuya, Mio, Toshiyuki. 2019. YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification. In Cancer research, 79, 5734-5745. doi:10.1158/0008-5472.CAN-18-3376. https://pubmed.ncbi.nlm.nih.gov/31391186/
2. Redin, Esther, Garrido-Martin, Eva M, Valencia, Karmele, Montuenga, Luis M, Calvo, Alfonso. 2022. YES1 Is a Druggable Oncogenic Target in SCLC. In Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17, 1387-1403. doi:10.1016/j.jtho.2022.08.002. https://pubmed.ncbi.nlm.nih.gov/35988891/
3. Piemonte, Katrina M, Ingles, Natasha N, Weber-Bonk, Kristen L, Singh, Salendra, Keri, Ruth A. . Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer. In Cancer research, 84, 3556-3573. doi:10.1158/0008-5472.CAN-23-2558. https://pubmed.ncbi.nlm.nih.gov/39037997/
4. Kook, Eunjin, Lee, JungYeol, Kim, Do-Hee. 2024. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer. In Archives of toxicology, 98, 1437-1455. doi:10.1007/s00204-024-03693-7. https://pubmed.ncbi.nlm.nih.gov/38443724/
5. Garmendia, Irati, Pajares, María J, Hermida-Prado, Francisco, Montuenga, Luis M, Agorreta, Jackeline. . YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. In American journal of respiratory and critical care medicine, 200, 888-899. doi:10.1164/rccm.201807-1292OC. https://pubmed.ncbi.nlm.nih.gov/31166114/
6. Ying, Xiaoling, Hu, Wenyu, Huang, Yapeng, Wu, Wenqi, Ji, Weidong. 2024. A Novel tsRNA, m7G-3' tiRNA LysTTT, Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11, e2400115. doi:10.1002/advs.202400115. https://pubmed.ncbi.nlm.nih.gov/38894581/
7. Miao, Daojia, Wang, Qi, Shi, Jian, Xiong, Zhiyong, Zhang, Xiaoping. 2023. N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway. In Cancer communications (London, England), 43, 480-502. doi:10.1002/cac2.12413. https://pubmed.ncbi.nlm.nih.gov/36860124/
智鼠故事 
